162 related articles for article (PubMed ID: 32361064)
1. Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
Yun F; Cheng C; Ullah S; Yuan Q
Eur J Med Chem; 2020 Jul; 198():112322. PubMed ID: 32361064
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
Cheng C; Yun F; Ullah S; Yuan Q
Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
[TBL] [Abstract][Full Text] [Related]
3. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP
Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Xie R; Li Y; Tang P; Yuan Q
Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
6. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
[TBL] [Abstract][Full Text] [Related]
7. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q
Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540
[TBL] [Abstract][Full Text] [Related]
9. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
10. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
[TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity.
El-Sattar NEAA; Badawy EHK; AbdEl-Hady WH; Abo-Alkasem MI; Mandour AA; Ismail NSM
Chem Pharm Bull (Tokyo); 2021; 69(1):106-117. PubMed ID: 33390512
[TBL] [Abstract][Full Text] [Related]
13. Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
Yun F; Cheng C; Ullah S; He J; Zahi MR; Yuan Q
Eur J Med Chem; 2019 Aug; 176():195-207. PubMed ID: 31103900
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
Mao PT; He WB; Mai X; Feng LH; Li N; Liao YJ; Zhu CS; Li J; Chen T; Liu SH; Zhang QM; He L
Bioorg Med Chem; 2022 Feb; 56():116599. PubMed ID: 35041998
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity.
Diao PC; Lin WY; Jian XE; Li YH; You WW; Zhao PL
Eur J Med Chem; 2019 Oct; 179():196-207. PubMed ID: 31254921
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
Cui H; Huang J; Lei Y; Chen Q; Hu Z; Niu J; Wei R; Yang K; Li H; Lu T; Zhu Y; Huang Y
Eur J Med Chem; 2022 Feb; 229():114082. PubMed ID: 34995925
[TBL] [Abstract][Full Text] [Related]
19. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
El-Naggar AM; El-Hashash MA; Elkaeed EB
Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.
Wu YZ; Ying HZ; Xu L; Cheng G; Chen J; Hu YZ; Liu T; Dong XW
Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700381. PubMed ID: 29708285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
